{"protocolSection": {"identificationModule": {"nctId": "NCT00624832", "orgStudyIdInfo": {"id": "CIGE025A2210"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels", "officialTitle": "A Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy of Xolair in an Allergen Bronchoprovocation Study in Asthmatic Populations Defined by Serum IgE Concentrations"}, "statusModule": {"statusVerifiedDate": "2011-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-02"}, "primaryCompletionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-02-18", "studyFirstSubmitQcDate": "2008-02-26", "studyFirstPostDateStruct": {"date": "2008-02-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-01-21", "resultsFirstSubmitQcDate": "2011-01-21", "resultsFirstPostDateStruct": {"date": "2011-02-14", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-04-12", "lastUpdatePostDateStruct": {"date": "2011-04-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Novartis", "oldOrganization": "Novartis"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}, "collaborators": [{"name": "Genentech, Inc.", "class": "INDUSTRY"}, {"name": "Tanox", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study was intended to demonstrate that patients with standard and high immunoglobulin E (IgE) levels can be protected from allergen induced broncho-constriction by Xolair"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "allergen challenge", "bronchoprovocation", "Methacholine challenge", "serum Immunoglobulin E", "Nitric Oxide", "skin prick test"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 60, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL)", "type": "EXPERIMENTAL", "description": "Patients with screening Immunoglobulin E (IgE) levels = 30-300 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.", "interventionNames": ["Drug: Xolair"]}, {"label": "Xolair (Immunoglobulin E (IgE) = 700-2000 IU/mL)", "type": "EXPERIMENTAL", "description": "Patients with screening Immunoglobulin E (IgE) levels = 700- 2000 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.", "interventionNames": ["Drug: Xolair"]}, {"label": "Xolair (Immunoglobulin E (IgE) = 301-699 IU/mL)", "type": "EXPERIMENTAL", "description": "Patients with screening Immunoglobulin E (IgE) levels = 301- 699 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.", "interventionNames": ["Drug: Xolair"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "By subcutaneous injection of a solution with a concentration of 125 mg/mL placebo in a supine position: Patients in Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL) group received doses of 150 mg to 375 mg of placebo every 2 or 4 weeks for 12 or 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL) group received doses of 450 mg, 525 mg, or 600 mg of placebo every 2 weeks for 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL) group received doses of 225 mg to 375 mg of placebo every 2 weeks for 6 weeks.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Xolair", "description": "Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;", "armGroupLabels": ["Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL)", "Xolair (Immunoglobulin E (IgE) = 301-699 IU/mL)", "Xolair (Immunoglobulin E (IgE) = 700-2000 IU/mL)"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo of Xolair (omalizumab), by subcutaneous injection of a solution with a concentration of 125 mg/mL in a supine position.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Early Phase Allergic Response After Treatment With Study Drug in Active and Placebo Patients", "description": "The EAR was defined as the maximum percent drop in forced expiratory volume in one second (FEV1) in the first 30 minutes after the challenge:\n\nEAR = 100\\* \\[ FEV1 (0) - Minimum FEV1 (10, 15, 30 min)\\] / FEV1 (0). For FEV1 (0), the \"best post saline (Control) FEV1\" was used. The EAR was analyzed using a linear (ANCOVA) model with a fixed effect for treatment groups and the EAR from the baseline challenge was used as a covariate.", "timeFrame": "Week 8, Week 16"}], "secondaryOutcomes": [{"measure": "Late Phase Allergic Response After Treatment With Study Drug in Active and Placebo Patients", "description": "Late-phase allergic response (LAR) was only determined for those patients who had an LAR \\>= 15% at baseline allergen bronchoprovocation testing. For Forced Expiratory Volume, FEV1 (0), the \"best post saline (Control) FEV1\" was used. LAR (%) = 100\\*\\[FEV1 (0) - Minimum FEV1 (3-8h)\\]/FEV1 (0).", "timeFrame": "Week 0, Week 8 and Week 16"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female adult patients, body weight between 40-150 kg aged 18-65 years (inclusive)\n* Patients diagnosed with asthma with Forced Expiratory Volume (FEV1) \u226565% of the predicted normal value for the patient\n* Positive skin prick test to a specific allergen\n* Patients had to demonstrate a Provocative Dose 20% FEV1 decline (PD20) response to an aeroallergen in the graded allergen bronchoprovocation testing (ABP) at screening\n\nExclusion Criteria:\n\n* Current active smokers\n* Patients who have been hospitalized or had emergency treatment for an asthma attack in the 12 months prior to study start\n* History of bleeding disorders\n* History of drug allergy\n* Pregnant women or nursing mothers\n* Females of childbearing potential, regardless of whether or not sexually active, if they are not using a reliable form of contraception (surgical contraception or double barrier methods (to be continued for at least two months following last dose) are acceptable).\n* Sexually active males who have not been sterilized and are not using a condom\n* History of immunocompromise, including a positive HIV\n* A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.\n* History of drug or alcohol abuse within 12 months of study start\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Novartis investigator site", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Novartis Investigator Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigator Site", "city": "Frankfurt", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigator Site", "city": "Munich", "country": "Germany", "geoPoint": {"lat": 48.13743, "lon": 11.57549}}, {"facility": "Novartis Investigator Site", "city": "Groningen", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "Novartis Investigator Site", "city": "Bloemfontein", "country": "South Africa", "geoPoint": {"lat": -29.12107, "lon": 26.214}}, {"facility": "Novartis Investigator Site", "city": "Durban", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL)", "description": "Patients with screening Immunoglobulin E (IgE) levels = 30-300 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "FG001", "title": "Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL)", "description": "Patients with screening Immunoglobulin E (IgE) levels = 700- 2000 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight."}, {"id": "FG002", "title": "Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL)", "description": "Patients with screening Immunoglobulin E (IgE) levels = 301- 699 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight."}, {"id": "FG003", "title": "Placebo Comparator", "description": "By subcutaneous injection of a solution with a concentration of 125 mg/mL placebo in a supine position: Patients in Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL) group received doses of 150 mg to 375 mg of placebo every 2 or 4 weeks for 12 or 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL) group received doses of 450 mg, 525 mg, or 600 mg of placebo every 2 weeks for 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL) group received doses of 225 mg to 375 mg of placebo every 2 weeks for 6 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "16"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "16"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "15"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Abnormal Laboratory Value", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL)", "description": "Patients with screening Immunoglobulin E (IgE) levels = 30-300 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "BG001", "title": "Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL)", "description": "Patients with screening Immunoglobulin E (IgE) levels = 700- 2000 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight."}, {"id": "BG002", "title": "Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL)", "description": "Patients with screening Immunoglobulin E (IgE) levels = 301- 699 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight."}, {"id": "BG003", "title": "Placebo Comparator", "description": "By subcutaneous injection of a solution with a concentration of 125 mg/mL placebo in a supine position: Patients in Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL) group received doses of 150 mg to 375 mg of placebo every 2 or 4 weeks for 12 or 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL) group received doses of 450 mg, 525 mg, or 600 mg of placebo every 2 weeks for 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL) group received doses of 225 mg to 375 mg of placebo every 2 weeks for 6 weeks."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "10"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "60"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "36", "spread": "11.9"}, {"groupId": "BG001", "value": "29", "spread": "11.0"}, {"groupId": "BG002", "value": "26", "spread": "6.0"}, {"groupId": "BG003", "value": "34", "spread": "10.4"}, {"groupId": "BG004", "value": "32", "spread": "10.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "26"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "34"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Early Phase Allergic Response After Treatment With Study Drug in Active and Placebo Patients", "description": "The EAR was defined as the maximum percent drop in forced expiratory volume in one second (FEV1) in the first 30 minutes after the challenge:\n\nEAR = 100\\* \\[ FEV1 (0) - Minimum FEV1 (10, 15, 30 min)\\] / FEV1 (0). For FEV1 (0), the \"best post saline (Control) FEV1\" was used. The EAR was analyzed using a linear (ANCOVA) model with a fixed effect for treatment groups and the EAR from the baseline challenge was used as a covariate.", "populationDescription": "Safety and Pharmacodynamic (PD) population. Although all patients had baseline EAR not all of them had a value determined for week 8 and 16 reducing the number evaluable for analysis particularly at week 8. Patients of first 2 Xolair groups received placebo treatment were pooled in one placebo group for analysis. No analysis on third Xolair groups.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of EAR", "timeFrame": "Week 8, Week 16", "groups": [{"id": "OG000", "title": "Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL)", "description": "Patients with screening Immunoglobulin E (IgE) levels = 30-300 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "OG001", "title": "Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL)", "description": "Patients with screening Immunoglobulin E (IgE) levels = 700- 2000 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight."}, {"id": "OG002", "title": "Placebo Comparator", "description": "By subcutaneous injection of a solution with a concentration of 125 mg/mL placebo in a supine position: Patients in Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL) group received doses of 150 mg to 375 mg of placebo every 2 or 4 weeks for 12 or 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL) group received doses of 450 mg, 525 mg, or 600 mg of placebo every 2 weeks for 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL) group received doses of 225 mg to 375 mg of placebo every 2 weeks for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}]}], "classes": [{"title": "Week 8 (n=12, 12, 13)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.3", "spread": "3.97"}, {"groupId": "OG001", "value": "5.6", "spread": "2.07"}, {"groupId": "OG002", "value": "23.1", "spread": "3.57"}]}]}, {"title": "Week 16 (n=14, 15, 15)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.8", "spread": "3.81"}, {"groupId": "OG001", "value": "5.1", "spread": "2.02"}, {"groupId": "OG002", "value": "20.0", "spread": "2.43"}]}]}]}, {"type": "SECONDARY", "title": "Late Phase Allergic Response After Treatment With Study Drug in Active and Placebo Patients", "description": "Late-phase allergic response (LAR) was only determined for those patients who had an LAR \\>= 15% at baseline allergen bronchoprovocation testing. For Forced Expiratory Volume, FEV1 (0), the \"best post saline (Control) FEV1\" was used. LAR (%) = 100\\*\\[FEV1 (0) - Minimum FEV1 (3-8h)\\]/FEV1 (0).", "populationDescription": "Safety and Pharmacodynamic (PD) population. Although all patients had baseline EAR not all of them had a value determined for week 8 and 16 reducing the number evaluable for analysis particularly at week 8. Patients of first 2 Xolair groups received placebo treatment were pooled in one placebo group for analysis. No analysis on third Xolair groups.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of LAR", "timeFrame": "Week 0, Week 8 and Week 16", "groups": [{"id": "OG000", "title": "Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL)", "description": "Patients with screening Immunoglobulin E (IgE) levels = 30-300 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "OG001", "title": "Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL)", "description": "Patients with screening Immunoglobulin E (IgE) levels = 700- 2000 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight."}, {"id": "OG002", "title": "Placebo Comparator", "description": "By subcutaneous injection of a solution with a concentration of 125 mg/mL placebo in a supine position: Patients in Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL) group received doses of 150 mg to 375 mg of placebo every 2 or 4 weeks for 12 or 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL) group received doses of 450 mg, 525 mg, or 600 mg of placebo every 2 weeks for 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL) group received doses of 225 mg to 375 mg of placebo every 2 weeks for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}]}], "classes": [{"title": "Week 0 (n=8, 3, 5)", "categories": [{"measurements": [{"groupId": "OG000", "value": "22.5", "spread": "6.12"}, {"groupId": "OG001", "value": "25.7", "spread": "12.62"}, {"groupId": "OG002", "value": "27.4", "spread": "7.27"}]}]}, {"title": "Week 8 (n=6, 1, 3)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.3", "spread": "12.13"}, {"groupId": "OG001", "value": "-3.5", "spread": "0.0"}, {"groupId": "OG002", "value": "19.1", "spread": "13.42"}]}]}, {"title": "Week 16 (n=7, 2, 4)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.23", "spread": "7.109"}, {"groupId": "OG001", "value": "1.5", "spread": "1.53"}, {"groupId": "OG002", "value": "12.3", "spread": "7.09"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "18- 26 weeks. Patients were dosed for 6 - 14 weeks depending on treatment group and adverse event data was collected until final study completion evaluation 12 weeks following last dose.", "eventGroups": [{"id": "EG000", "title": "Xolair (IgE= 30- 300 IU/mL)", "description": "Patients with screening IgE levels= 30-300 IU/mL. Participants received subcutaneous injections of Xolair(Omalizumab) every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.", "seriousNumAffected": 1, "seriousNumAtRisk": 18, "otherNumAffected": 9, "otherNumAtRisk": 18}, {"id": "EG001", "title": "Xolair (IgE= 700- 2000 IU/mL)", "description": "Patients with screening IgE levels= 700- 2000 IU/mL. Participants received subcutaneous injections of Xolair(Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.", "seriousNumAffected": 1, "seriousNumAtRisk": 16, "otherNumAffected": 15, "otherNumAtRisk": 16}, {"id": "EG002", "title": "Xolair (IgE= 301- 699 IU/mL)", "description": "Patients with screening IgE levels= 301- 699 IU/mL. Participants received subcutaneous injections of Xolair(Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.", "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 6, "otherNumAtRisk": 10}, {"id": "EG003", "title": "Placebo Comparator", "description": "Placebo comparator", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 12, "otherNumAtRisk": 16}], "seriousEvents": [{"term": "Malignant melanoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Papilloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}], "otherEvents": [{"term": "Lymphadenopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Ear pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Conjunctivitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Conjunctivitis allergic", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Eye irritation", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Eye pruritus", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Gastrointestinal disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Infusion site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Infusion site haematoma", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Infusion site induration", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Infusion site irritation", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Infusion site swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Infusion site warmth", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Injection site swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Seasonal allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Eczema infected", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Herpes virus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Infectious mononucleosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Laryngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 16}]}, {"term": "Oral herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Oral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Pilonidal cyst", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Tinea pedis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Excoriation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Sunburn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Tooth injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Wound complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Blood pressure diastolic increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Blood pressure systolic increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Myosclerosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Dysgeusia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 16}]}, {"term": "Sleep disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Dysmenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Bronchial obstruction", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Bronchospasm", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Productive cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Dermatitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Dermographism", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Neurodermatitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Photosensitivity reaction", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069444", "term": "Omalizumab"}], "ancestors": [{"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M19117", "name": "Immunoglobulins, Intravenous", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M413", "name": "Omalizumab", "asFound": "Pathological", "relevance": "HIGH"}, {"id": "M12507", "name": "Nitric Oxide", "relevance": "LOW"}, {"id": "M18666", "name": "Methacholine Chloride", "relevance": "LOW"}, {"id": "M10121", "name": "Immunoglobulin E", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}]}}, "hasResults": true}